Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengda Pharmaceuticals CoSZSE:301201 +2.26%75 Days Payable is 163.40 as of Mar. 2026, which is 74% above its 10-year median of 93.95. GuruFocus rates SZSE:301201 with a GF Score™ of 75/100 and a GF Value™ of ¥30.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 927 Drug Manufacturers companies, Chengda Pharmaceuticals Co ranks better than 84.36% on this metric.
The historical rank and industry rank for Chengda Pharmaceuticals Co's Days Payable or its related term are showing as below:
SZSE:301201'
s Days Payable Range Over the Past 10 Years
Min: 75.3 Med: 93.95 Max: 315.32
Current: 199.81
During the past 12 years, Chengda Pharmaceuticals Co's highest Days Payable was 315.32. The lowest was 75.30. And the median was 93.95.
SZSE:301201's Days Payable is ranked better than 84.36% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs SZSE:301201: 199.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's Days Payable falls into.
Chengda Pharmaceuticals Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengda Pharmaceuticals Co (SZSE:301201) has a Days Payable of 163.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chengda Pharmaceuticals Co and its competitors. This is 74% above median its historical median of 93.95. Over the past decade, Chengda Pharmaceuticals Co's Days Payable has ranged from 75.30 to 315.32. According to the industry distribution chart, Chengda Pharmaceuticals Co ranks #145 out of 927 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Chengda Pharmaceuticals Co's Days Payable too high?
Chengda Pharmaceuticals Co's current Days Payable of 163.40 is 74% above median its 10-year median of 93.95. Over the past 10 years, this metric has ranged from a low of 75.30 to a high of 315.32. The Drug Manufacturers industry median Days Payable is 90.38. Chengda Pharmaceuticals Co's value of 163.40 is 80.8% above this industry median. Based on the distribution chart, Chengda Pharmaceuticals Co ranks #145 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chengda Pharmaceuticals Co ranks #145 out of 927 companies for Days Payable. This places Chengda Pharmaceuticals Co in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Chengda Pharmaceuticals Co's value of 163.40 is 80.8% above this benchmark. Historically, Chengda Pharmaceuticals Co's own Days Payable has ranged from 75.30 to 315.32 over the past decade. While the company's 10-year median is 93.95 vs. the industry median of 90.38, Chengda Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengda Pharmaceuticals Co's current Days Payable of 163.40 is 80.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chengda Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengda Pharmaceuticals Co's current Days Payable is 163.40, which is 74% above median its own 10-year median of 93.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥37.94 — trading 24.6% above its estimated fair value. The current Days Payable is 163.40, which is 74% above median its 10-year median of 93.95 and 80.8% above the Drug Manufacturers industry median of 90.38. Chengda Pharmaceuticals Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current Days Payable is 163.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥37.94 is trading 24.6% above its estimated GF Value™ of ¥30.45.
GuruFocus considers Chengda Pharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SZSE:301201:
Days Payable: 163.40 (74% above median its 10-year median of 93.95)
GF Value™: ¥30.45 vs. price of ¥37.94 (24.6% above fair value)
Industry Position: 80.8% above the Drug Manufacturers median (#145 of 927)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
75GF Score
Get the complete analysis for SZSE:301201
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
